Amarantus Bioscience Holdings Inc (AMBS)

[MUKA1]

True, but the "major analyst covering $AMBS" also blogged yesterday:

Given the 45% haircut in Amarantus stock on July 31, 2014, we believe today is an attractive entry opportunity. Nothing has materially changed with respect to the CLIA opportunity ahead with LymPro. Development programs with MANF and eltoprazine remain on tract, and as of August 1, 2014 we estimate the company has approximately $3.5 million in cash on hand, or enough to fund operations into 2015 without significant additional dilution under the Lincoln Park equity agreement.

http://bionapcfa.blogspot.com/2014/08/why-im-still-optimistic-on-lympro-and.html